A Complete Guide to GLP-1 Receptor Agonists and Incretin Mimetics for Diabetes and Obesity | Research

The takeaway

Incretin mimetics including GLP-1 and GIP receptor agonists are now first-line treatments for type 2 diabetes and obesity, with benefits extending to sleep apnea, heart failure, and other comorbidities.

First-line treatment status
Incretin mimetics have achieved first-line status for both type 2 diabetes and obesity treatment due to their high efficacy and multi-system benefits

What the researchers found

Incretin mimetics, including GLP-1 and GIP receptor agonists, have achieved first-line treatment status for type 2 diabetes and obesity due to high efficacy and positive impact on comorbidities such as sleep apnea and heart failure. Multiple agents are available with varying durations of action, dosing frequencies, and delivery devices. Patients require education on proper administration, expected side effects, and nutrition considerations. Future developments include dual- and triple-mechanism agents and new oral formulations in a rapidly developing therapeutic pipeline.

Why it matters

GLP-1 receptor agonists represent one of the most important therapeutic advances in decades, transforming treatment for both diabetes and obesity. This review serves as a practical guide for healthcare providers managing patients on these medications, addressing not just efficacy data but the real-world challenges of dosing, side effects, and nutritional support that affect treatment success.

How the study worked

Narrative review of current literature covering FDA-approved indications of incretin mimetics, clinical evidence supporting their use, practical guidance for healthcare professionals, and the future therapeutic pipeline.

What this study cannot tell us

This is a narrative review, not a systematic review or meta-analysis. It focuses on FDA-approved indications and the US healthcare context, which may not apply globally. The rapidly evolving pipeline means some information may quickly become outdated. Comparative effectiveness between different incretin mimetics is not comprehensively addressed. Long-term safety data for newer agents is still accumulating.

How to read the evidence

This is a narrative review published in Nutrition in Clinical Practice, an official publication of ASPEN. It synthesizes evidence from clinical trials and current practice guidelines but does not present new primary data or use systematic review methodology.

When this study was published

Published in 2025, this is a very current review capturing the state of the incretin mimetic field including the latest FDA-approved agents and pipeline developments.

The bigger picture

The incretin mimetic revolution has expanded far beyond diabetes. With growing evidence for benefits in cardiovascular disease, kidney disease, liver disease, and possibly neurodegeneration, these peptide-based therapies are reshaping multiple medical specialties. The pipeline of dual and triple agonists promises even greater efficacy, while oral formulations could dramatically expand access.

Questions still open

Will dual- and triple-agonist incretin mimetics offer clinically meaningful advantages over current single-target GLP-1 agonists?
How should nutrition counseling be tailored for patients on incretin mimetics to optimize outcomes and minimize side effects?
As these drugs expand to new indications beyond diabetes and obesity, how will healthcare systems manage the growing demand?

Common questions

What are incretin mimetics and how are they different from insulin?

Incretin mimetics are drugs that mimic natural gut hormones (incretins) like GLP-1 that are released after eating. Unlike insulin, which directly lowers blood sugar, incretin mimetics stimulate insulin release only when blood sugar is high, reduce appetite, slow digestion, and promote weight loss — making them effective for both diabetes and obesity.

What new incretin drugs are coming in the future?

The pipeline includes dual agonists (targeting both GLP-1 and GIP receptors, like tirzepatide) and triple agonists (targeting GLP-1, GIP, and glucagon receptors). New oral formulations are also being developed to replace injections. These next-generation drugs aim for even greater weight loss and metabolic benefits.

Read the original research

Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 40(2), 327-349

View on PubMed ↗Publisher’s paper ↗

Citation

Zupec, Jason; Munger, Rebecca; Scaletta, Alice; Quinn, Diane H. (2025). Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 40(2), 327-349. https://doi.org/10.1002/ncp.11279